Mastitis, metritis, agalactia (MMA)

*<p>p<0.05 comparing trend across each CD4 count category within an age category.</p>¶<p>p<0.01 comparing trend across each CD4 count category within an age category.</p

Factors associated with higher levels of cardiovascular risk.

<p>Age is a categorical variable defined by three age categories: 16–35, 36–45 and <45 years.</p><p>CD4 count is a binary variable: ≥200 and <200 cells/mm³.</p><p>BMI was not included as a covariate in the risk factor analysis because BMI≥25 kg/m² is one of the cardiovascular risk factors.</p>*<p>HTN: hypertension.</p

Factors associated with higher levels of cardiovascular risk among patients using protease inhibitors.

<p>Age is a categorical variable defined by three age categories: 16–35, 36–45 and <45 years.</p><p>CD4 count is a binary variable: ≥200 and <200 cells/mm³.</p><p>BMI was not included as a covariate in the risk factor analysis because BMI≥25 kg/m² is one of the cardiovascular risk factors.</p>*<p>HTN: hypertension.</p

Summary of Clinical Characteristics.

<p><b><u>BP</u></b>: blood pressure. <b><u>BMI</u></b><u>:</u> body mass index. <b><u>eGFR</u></b>: estimated glomerular filtration rate. <b><u>CKD</u></b>: chronic kidney disease. <b><u>PI</u></b>: protease inhibitor. <b><u>ART:</u></b> anti-retroviral therapy.</p>§<p>The sample size was smaller for males (n = 1,471) and females (n = 2,494).</p>???<p>The sample size was smaller for males (n = 3,078) and females (n = 4,932).</p><p>*<b><u>Prehypertension</u></b> is defined as SBP 120–139 mmHg or DBP 80–89 mmHg.</p>¶<p><b><u>Hypertension</u></b> is defined as SBP≥140 mmHg or DBP≥90 mmHg. Use of anti-hypertensive medications was not routinely assessed. <b><u>Overweight/Obese</u></b> is defined as BMI≥25 kg/m².</p>±<p>Based on the following factors: SBP≥140 mmHg, DBP≥90 mmHg and BMI≥25 kg/m².</p

Risk of Clinically Significant Drug Interaction by Individual Drug.

<p> <b><i>‡: Fisher exact test.</i></b></p

Odds Ratios for Clinically Significant Drug Interaction by CD4 Count Decile.

<p>Odds Ratios for Clinically Significant Drug Interaction by CD4 Count Decile.</p

Factors Associated with Risk for Developing a Clinically Significant Drug Interaction.

<p>Summary statistics are based on original data (ignoring the missing observations). However, both the unadjusted (univariate) and adjusted (bivariate) odds ratios (and their 95% confidence intervals) were computed after a multiple imputation analysis (of 100 iterations) to replace the missing observations for age, CD4 count, weight and WHO Stage. The odds ratios were computed using logistic regression models (with all variables forced into the model in the adjusted/multivariate analysis).</p><p> <i>*: missing observations replaced using multiple imputation (100 iterations).</i></p

Prevalence and Nature of Clinically Significant Drug Interactions in Kenya.

<p> <b>*occurring in 334 individuals.</b></p

Results of the Cox proportional hazards model of patient dropout.

*<p>Wald test.</p

Kaplan-Meier estimates of patient survival based on methods described in Table 3.

<p>Time is in months since start of CART.</p